Monitor updates from Pfizer regarding regulatory submissions for LB6V (Lyme vaccine), which could be a significant catalyst if accepted by regulators. The conferences may provide additional color on pipeline progress, but no near-term stock-moving news is expected from this filing alone.
Price Chart
Executive Summary
Valneva announced participation in investor conferences (Jefferies, Oddo BHF, BNP Paribas) and a travel medicine conference, with key discussion topics including its commercial vaccines and the Lyme disease candidate LB6V (partnered with Pfizer, which reported positive Phase 3 results and plans regulatory submissions). This is a routine update with no material financial or operational data.
Key Facts
- Valneva to present and hold investor meetings at Jefferies Global Healthcare Conference (June 3), Oddo BHF Nextcap Forum (June 12), and BNP Paribas SMID Cap Conference (June 24).
- LB6V (Lyme disease vaccine candidate) partnered with Pfizer; Pfizer reported positive Phase 3 results and plans regulatory submissions.
- Valneva will be a Gold Sponsor at the 10th Northern European Conference on Travel Medicine (June 3-5).
- No financial figures or guidance were disclosed in the filing.
Financial Impact
No financial impact disclosed; event is a routine conference participation announcement.
Risk Factors
- Regulatory submissions for LB6V may face delays or unfavorable outcomes.
- Commercial vaccine sales may underperform expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-039308 |
| Document: a6-kcoverpagetemplate.htm | 0001628280-26-039308 |
| Document: 0001628280-26-039308-index-headers.html | 0001628280-26-039308 |
| Document: 0001628280-26-039308-index.html | 0001628280-26-039308 |
| Document: 0001628280-26-039308.txt | 0001628280-26-039308 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 17, 2026 15w ago | EFFECT | $5.35 $6.66 | ▲ +24.49% | ▲ +21.34% | $5.74 (+7.29%) |
Jun 5, 2026 17w ago | 6-K | $5.48 $6.30 | ▲ +14.96% | ▲ +10.96% | $5.74 (+4.74%) |
Jun 1, 2026 17w ago | 6-K | $5.95 $6.78 | ▲ +13.95% | ▲ +12.72% | $5.74 (−3.53%) |
May 5, 2026 21w ago | 6-K | $5.29 $5.09 | ▼ −3.85% | ▼ −6.59% | $5.74 (+8.51%) |
Mar 26, 2026 27w ago | 6-K | $6.32 $5.35 | ▼ −15.35% | ▼ −29.30% | $5.74 (−9.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access